MedDRA preferred term

Therapy cessation: adverse event reports recording this term

50,419 reports to FDA record it, 2006–2026; 0.2% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

50,419
reports recording the term: 0.2% of all reports; 3,317
reports, 12 months to June 2026: 3,618 in the 12 months before; 44.5%
marked serious by the reporter: 57.4% across all reports; 2.7%
record death among outcomes, as reported: 9.1% across all reports

"Therapy cessation" is a MedDRA preferred term recorded in 50,419 adverse event reports received by FDA, 0.2% of the database, from July 2006 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

3,317 reports recorded it in the 12 months to June 2026, close to the 3,618 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 44.5% are marked serious, 2.7% include death among the outcomes and 23.4% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Ampyra, Enbrel and Humira. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Ampyra	Potassium channel blocker	4,419	7.9%
Enbrel	Tumor necrosis factor blocker	2,074	0.4%
Humira	—	1,729	0.3%
Zytiga	Cytochrome P450 17A1 inhibitor	1,398	5.5%
Oxbryta	—	1,028	4.7%
Juxtapid	—	791	21.3%
Clozaril	Atypical antipsychotic	690	1.4%
Cosentyx	Interleukin-17A antagonist	627	0.4%
Capecitabine	Nucleoside metabolic inhibitor	611	1.2%
Ibrance	Kinase inhibitor	598	0.7%
Xeljanz	Janus kinase inhibitor	590	0.4%
Tecfidera	—	541	0.5%
Forteo	Parathyroid hormone analog	518	0.5%
Makena	—	477	2.1%
Otezla	Phosphodiesterase 4 inhibitor	476	0.4%
Dalfampridine	Potassium channel blocker	434	7.5%
Latuda	Atypical antipsychotic	425	2.6%
Tyvaso	Prostacycline vasodilator	422	1.5%
Orencia	Selective T cell costimulation modulator	404	0.4%
Taltz	Interleukin-17A antagonist	395	1.2%
Stelara	Interleukin-12 antagonist	392	0.5%
Cequa	Calcineurin inhibitor immunosuppressant	359	11.8%
Xifaxan	Rifamycin antibacterial	339	2.4%
Risperdal	Atypical antipsychotic	333	0.6%
Rytary	Aromatic amino acid	325	3.3%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.2% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Potassium channel blocker	4,879	7.5%	7.5%
Atypical antipsychotic	3,110	0.5%	0.1%
Tumor necrosis factor blocker	3,054	0.3%	0.3%
Kinase inhibitor	2,670	0.3%	0.1%
Cytochrome P450 17A1 inhibitor	1,577	4.2%	1.6%
Interleukin-17A antagonist	1,022	0.5%	0.2%
Janus kinase inhibitor	1,005	0.3%	0.1%
Retinoid	899	1.4%	0.3%
Corticosteroid	849	0.1%	0%
Prostacycline vasodilator	843	0.7%	0.4%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.2%94

2 to 111%485

12 to 171.6%804

18 to 4413.8%6,969

45 to 6425%12,592

65 to 7412.9%6,491

75 and over8.9%4,485

Age not given36.7%18,499

Patient sex

Female56.9%28,698

Male35.1%17,688

Not given8%4,033

Grey bar: all 20,646,523 reports in the database. 90.7% of these reports give the United States as the country.

Questions about "Therapy cessation"

What does "Therapy cessation" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record therapy cessation?

50,419 reports through June 2026 (0.2% of all reports), 3,317 of them in the latest 12 months.

Which drugs appear most often in these reports?

Ampyra (4,419), Enbrel (2,074), Humira (1,729), Zytiga (1,398) and Oxbryta (1,028). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.